Celmatix Achieves Milestone for PCOS Drug Program
Second novel PCOS drug target from Celmatix-Evotec Alliance, identified by Celmatix, progresses into hit-identification NEW YORK--(BUSINESS WIRE)--Celmatix Inc., a biotechnology company focused on ovarian biology, today announced that a fourth milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG…
